Mohammad Esfini Farahani

Mr. Mohammad Esfini Farahani

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MFMohammad Esfini Farahani
Mohammad Esfini Farahani
YZYanquan Zhang
Yanquan Zhang
AAAmos Olalekan Akinyemi
Amos Olalekan Akinyemi
FSFatemeh Seilani
Fatemeh Seilani
RARakibul Alam
Rakibul Alam
XLXiaoqi Liu
Xiaoqi Liu
Prostate cancer (PCa) is a highly heterogeneous disease, with castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) representing its most aggressive and therapy-resistant forms. Emerging evidence indicates that lineage plasticity—driven by key transcription factors such as Octamer Binding Factor 4 (OCT4)—plays a crucial role in therapeutic resistance and disease progression. OCT4, in coordination with SOX2 and NANOG, acts as a master regulator of stemness and is frequently upregulated in prostate cancer stem cells (PCSCs). This upregulation contributes to tumor initiation, metastasis, and resistance to both androgen deprivation therapy (ADT) and chemotherapy. In this review, we explore the role of OCT4 in mediating lineage plasticity in prostate cancer, with particular emphasis on its involvement in treatment resistance and neuroendocrine differentiation. We also examine therapeutic strategies aimed at targeting OCT4 directly, such as microRNA-mediated suppression, small-molecule inhibitors, and suicide gene therapy, as well as indirect approaches that modulate OCT4 expression via FGFR and NF-κB signaling pathways. While these strategies offer promising avenues, challenges such as adaptive resistance and the intricate signaling networks within PCSCs remain significant hurdles. A deeper understanding of the molecular mechanisms underlying OCT4-driven plasticity may pave the way for novel therapeutic approaches and improved outcomes in advanced prostate cancer.

31 December 2025 in Reproductive Biology
Verified
Journal Article
Closed access
SBSina Baharaghdam
Sina Baharaghdam
SKShima Karimi
Shima Karimi
MFMohammad Esfini Farahani
Mohammad Esfini Farahani
LALeili Aghebati-Maleki
Leili Aghebati-Maleki
MYMehdi Yousefi
Mehdi Yousefi

23 January 2026 in iNew Medicine
Verified
Journal Article
Open access
AAAmos Olalekan Akinyemi
Amos Olalekan Akinyemi
RARakibul Alam
Rakibul Alam
MHMithu Howlader
Mithu Howlader
MFMohammad Esfini Farahani
Mohammad Esfini Farahani
LGLixiang Gu
Lixiang Gu
ZLZhiguo Li
Zhiguo Li
HSPA5 (also known as GRP78/BiP) is a master regulator of the endoplasmic reticulum (ER) stress response and a key node in the proteostasis network. In neuroendocrine prostate cancer (NEPC), an aggressive, therapy‐refractory lineage that emerges under pressure from androgen receptor (AR) directed therapies, GRP78 is upregulated and co‐opted to maintain malignant cell survival. Beyond its canonical chaperone activity, GRP78 orchestrates adaptive unfolded protein response (UPR) signaling, buffers secretory stress, and stabilizes oncogenic proteomes. These functions collectively allow NEPC cells to evade apoptosis, tolerate proteotoxic stress, and resist next generation therapeutics. This review explores the emerging role of GRP78 as a therapeutic vulnerability in NEPC. We integrate evidence from proteostasis biology, lineage plasticity, and tumor microenvironment remodeling, and highlight experimental and clinical strategies targeting GRP78 directly (e.g., chaperone inhibitors, antibody therapy, peptide displacement) or indirectly through the proteostasis machinery (e.g., ERAD modulators, proteasome inhibitors, and UPR reprogramming). By reframing NEPC not only as a lineage plastic tumor but also as a proteostasis‐addicted state, we propose that GRP78 centered intervention is a promising route to break the current therapeutic ceiling.